Temple, Robert

Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration

Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ

Suicide and Self-Harm StudiesTreatment of Major Depression

Cited by 609

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R. (2019) · New England Journal of Medicine

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 333

New therapies from old medicines

Chen, S. T., Dou, J., Temple, R., Agarwal, R., Wu, K.-M., & Walker, S. (2008) · Nature Biotechnology

Complementary and Alternative Medicine StudiesMedicinal Plant Research

Cited by 101

Charting a path toward combination therapy for Alzheimer’s disease

Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., et al. (2015) · Expert Review of Neurotherapeutics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 37

How FDA currently makes decisions on clinical studies

Temple, R. (2005) · Clinical Trials

Statistical Methods in Clinical TrialsPharmaceutical industry and healthcare

Cited by 31